This grant is for promoting preclinical and patient-based studies investigating the mechanisms by which incretin mimetics affect cancer risk. The National Institutes of Health seeks talented scientists to explore how these agents, including GLP-1, GIP-1, or dual GLP-1/GIP-1 agents, influence long-term cancer outcomes rather than immediate effects like weight loss or diabetes. Current data suggests incretin mimetics may both increase and decrease the risk of various obesity-related cancers. The purpose is to understand these complex impacts comprehensively, encouraging research into the precise biological pathways involved in their interaction with cancer development.
Opportunity ID: 349964
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-23-279 |
| Funding Opportunity Title: | Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.393 — Cancer Cause and Prevention Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Aug 23, 2023 |
| Last Updated Date: | Nov 18, 2024 |
| Original Closing Date for Applications: | Jan 07, 2027 |
| Current Closing Date for Applications: | Nov 17, 2024 |
| Archive Date: | Dec 17, 2024 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | County governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Special district governments Private institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) City or township governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: |
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-23-279.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| Update close date per reissued NOFO PAR-25-069. | Nov 18, 2024 | |
| Aug 23, 2023 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-23-279 |
| Funding Opportunity Title: | Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.393 — Cancer Cause and Prevention Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Aug 23, 2023 |
| Last Updated Date: | Nov 18, 2024 |
| Original Closing Date for Applications: | Jan 07, 2027 |
| Current Closing Date for Applications: | Nov 17, 2024 |
| Archive Date: | Dec 17, 2024 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | County governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Special district governments Private institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) City or township governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: |
The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-23-279.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-23-279 |
| Funding Opportunity Title: | Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.393 — Cancer Cause and Prevention Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Aug 23, 2023 |
| Last Updated Date: | Aug 23, 2023 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Jan 07, 2027 |
| Archive Date: | Feb 12, 2027 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | For profit organizations other than small businesses State governments Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses City or township governments Public housing authorities/Indian housing authorities Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) County governments Native American tribal governments (Federally recognized) Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The goal of the proposed funding announcement is twofold, to promote preclinical and patient based studies examining the mechanism(s) through which incretin mimetics (including agonists or antagonists of GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) impact cancer risk, and to draw talented scientists who understand the dynamic changes caused by these agents to investigate the mechanisms of how these agents influence cancer risk rather than shorter term outcomes such as weight loss and diabetes. The data thus far suggests that these agents may increase the risk of some, while decreasing the risk of other obesity related cancers. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-23-279.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Related Documents
Folder 349964 Full Announcement-PAR-23-279 -> PAR-23-279-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00282959 | Jan 05, 2024 | Nov 19, 2024 | View | |
| FORMS-I | Use for due dates on or after January 25, 2025 | PKG00288603 | Nov 07, 2024 | Nov 19, 2024 | View |
Package 1
Mandatory forms
349964 RR_SF424_5_0-5.0.pdf
349964 PHS398_CoverPageSupplement_5_0-5.0.pdf
349964 RR_OtherProjectInfo_1_4-1.4.pdf
349964 PerformanceSite_4_0-4.0.pdf
349964 RR_KeyPersonExpanded_4_0-4.0.pdf
349964 PHS398_ResearchPlan_5_0-5.0.pdf
349964 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
349964 RR_Budget_3_0-3.0.pdf
349964 RR_SubawardBudget30_3_0-3.0.pdf
349964 PHS398_ModularBudget_1_2-1.2.pdf
349964 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
349964 RR_SF424_5_0-5.0.pdf
349964 PHS398_CoverPageSupplement_5_0-5.0.pdf
349964 RR_OtherProjectInfo_1_4-1.4.pdf
349964 PerformanceSite_4_0-4.0.pdf
349964 RR_KeyPersonExpanded_4_0-4.0.pdf
349964 PHS398_ResearchPlan_5_0-5.0.pdf
349964 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
349964 RR_Budget_3_0-3.0.pdf
349964 RR_SubawardBudget30_3_0-3.0.pdf
349964 PHS398_ModularBudget_1_2-1.2.pdf
349964 PHS_AssignmentRequestForm_4_0-4.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
